{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:44:50Z","timestamp":1792043090360,"version":"4.4.0"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02589-2","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:33:30Z","timestamp":1745825610000},"page":"1739-1758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism"],"prefix":"10.1007","volume":"48","author":[{"given":"Luigi","family":"Barrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Caprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastio","family":"Perrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Camajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Crafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gangitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sciacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Albertelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Aimaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4931","authenticated-orcid":false,"given":"Giovanna","family":"Muscogiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2589_CR1","doi-asserted-by":"crossref","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al (2023) Addendum. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care.;46(Suppl. 1):S19-S40. Diabetes Care. 2023;46(9):1715","DOI":"10.2337\/dc23-ad08"},{"issue":"2","key":"2589_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40618-015-0404-6","volume":"39","author":"MG Baroni","year":"2016","unstructured":"Baroni MG, Giorgino F, Pezzino V, Scaroni C, Avogaro A (2016) Italian society for the study of diabetes (SID)\/Italian endocrinological society (SIE) guidelines on the treatment of hyperglycemia in Cushing\u2019s syndrome and acromegaly. J Endocrinol Invest 39(2):235\u2013255","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2589_CR3","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2337\/dc18-1293","volume":"42","author":"Y Akehi","year":"2019","unstructured":"Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y et al (2019) High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: A large, multicenter cohort study in Japan. Diabetes Care 42(5):938\u2013945","journal-title":"Diabetes Care"},{"key":"2589_CR4","doi-asserted-by":"crossref","unstructured":"Popoviciu MS, Paduraru L, Nutas RM, Ujoc AM, Yahya G, Metwally K et al (2023) Diabetes mellitus secondary to endocrine diseases: an update of diagnostic and treatment particularities. Int J Mol Sci. 24(16):12676.","DOI":"10.3390\/ijms241612676"},{"key":"2589_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fendo.2018.00358","volume":"9","author":"F Ferrau","year":"2018","unstructured":"Ferrau F, Albani A, Ciresi A, Giordano C, Cannavo S (2018) Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol (Lausanne) 9:358","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2589_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12020-023-03492-7","volume":"82","author":"M Moustaki","year":"2023","unstructured":"Moustaki M, Paschou SA, Vakali E, Xekouki P, Ntali G, Kassi E et al (2023) Secondary diabetes mellitus in pheochromocytomas and paragangliomas. Endocrine 82(3):467\u2013479","journal-title":"Endocrine"},{"issue":"2","key":"2589_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and Non-Functional pancreatic neuroendocrine tumors. Neuroendocrinology 103(2):153\u2013171","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2589_CR8","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1210\/clinem\/dgac006","volume":"107","author":"OH Roa Duenas","year":"2022","unstructured":"Roa Duenas OH, Van der Burgh AC, Ittermann T, Ligthart S, Ikram MA, Peeters R et al (2022) Thyroid function and the risk of prediabetes and type 2 diabetes. J Clin Endocrinol Metab 107(6):1789\u20131798","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2589_CR9","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with Pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446\u20133453","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2589_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-023-03339-1","volume":"81","author":"M Moustaki","year":"2023","unstructured":"Moustaki M, Paschou SA, Xekouki P, Kotsa K, Peppa M, Psaltopoulou T et al (2023) Secondary diabetes mellitus in acromegaly. Endocrine 81(1):1\u201315","journal-title":"Endocrine"},{"issue":"4","key":"2589_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11102-023-01322-7","volume":"26","author":"TNA Slagboom","year":"2023","unstructured":"Slagboom TNA, van Bunderen CC, De Vries R, Bisschop PH, Drent ML (2023) Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary 26(4):319\u2013332","journal-title":"Pituitary"},{"issue":"5","key":"2589_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.5603\/EP.a2016.0031","volume":"67","author":"C Wen-Ko","year":"2016","unstructured":"Wen-Ko C, Szu-Tah C, Feng-Hsuan L, Chen-Nen C, Ming-Hsu W, Jen-Der L (2016) The impact of diabetes mellitus on the survival of patients with acromegaly. Endokrynol Pol 67(5):501\u2013506","journal-title":"Endokrynol Pol"},{"issue":"2","key":"2589_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N Moller","year":"2009","unstructured":"Moller N, Jorgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152\u2013177","journal-title":"Endocr Rev"},{"issue":"2","key":"2589_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11102-020-01092-6","volume":"24","author":"B Biagetti","year":"2021","unstructured":"Biagetti B, Aulinas A, Casteras A, Perez-Hoyos S, Simo R (2021) HOMA-IR in acromegaly: a systematic review and meta-analysis. Pituitary 24(2):146\u2013158","journal-title":"Pituitary"},{"issue":"2","key":"2589_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11892-017-0838-7","volume":"17","author":"AM Hannon","year":"2017","unstructured":"Hannon AM, Thompson CJ, Sherlock M (2017) Diabetes in patients with acromegaly. Curr Diab Rep 17(2):8","journal-title":"Curr Diab Rep"},{"issue":"4","key":"2589_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.beem.2005.07.003","volume":"19","author":"P Kovacs","year":"2005","unstructured":"Kovacs P, Stumvoll M (2005) Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 19(4):625\u2013635","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"45","key":"2589_CR17","doi-asserted-by":"publisher","first-page":"37489","DOI":"10.1074\/jbc.M506967200","volume":"280","author":"LA Barbour","year":"2005","unstructured":"Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD et al (2005) Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 280(45):37489\u201337494","journal-title":"J Biol Chem"},{"issue":"5","key":"2589_CR18","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94(5):1500\u20131508","journal-title":"J Clin Endocrinol Metab"},{"key":"2589_CR19","doi-asserted-by":"crossref","unstructured":"Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E et al (2018) Somatostatin analogs and glucose metabolism in acromegaly: A Meta-analysis of prospective interventional studies. J Clin Endocrinol Metab104(7):2892-2902.","DOI":"10.1210\/jc.2018-02281"},{"issue":"1","key":"2589_CR20","doi-asserted-by":"publisher","first-page":"e00033","DOI":"10.1002\/edm2.33","volume":"2","author":"D Cappellani","year":"2019","unstructured":"Cappellani D, Urbani C, Sardella C, Scattina I, Marconcini G, Lupi I et al (2019) Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients. Endocrinol Diabetes Metab 2(1):e00033","journal-title":"Endocrinol Diabetes Metab"},{"issue":"11","key":"2589_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M et al (2014) Pasireotide versus continued treatment with octreotide or Lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2589_CR22","doi-asserted-by":"publisher","first-page":"1250822","DOI":"10.3389\/fendo.2024.1250822","volume":"15","author":"U Feldt-Rasmussen","year":"2024","unstructured":"Feldt-Rasmussen U, Bolanowski M, Zhang SL, Yu Y, Witek P, Kalra P et al (2024) Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing\u2019s disease receiving Pasireotide treatment: post hoc analyses from the SOM230B2219 study. Front Endocrinol (Lausanne) 15:1250822","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2589_CR23","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1007\/s00125-007-0815-9","volume":"50","author":"K Eckardt","year":"2007","unstructured":"Eckardt K, May C, Koenen M, Eckel J (2007) IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50(12):2534\u20132543","journal-title":"Diabetologia"},{"issue":"2","key":"2589_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.mayocp.2021.11.007","volume":"97","author":"N Ershadinia","year":"2022","unstructured":"Ershadinia N, Tritos NA (2022) Diagnosis and treatment of acromegaly: an update. Mayo Clin Proc 97(2):333\u2013346","journal-title":"Mayo Clin Proc"},{"key":"2589_CR25","doi-asserted-by":"publisher","first-page":"3015854","DOI":"10.1155\/2018\/3015854","volume":"2018","author":"M Shen","year":"2018","unstructured":"Shen M, Wang M, He W, He M, Qiao N, Ma Z et al (2018) Impact of Long-Acting somatostatin analogues on glucose metabolism in acromegaly: A Hospital-Based study. Int J Endocrinol 2018:3015854","journal-title":"Int J Endocrinol"},{"issue":"8","key":"2589_CR26","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1210\/jc.2008-2627","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G et al (2009) Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 94(8):2907\u20132914","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2589_CR27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s11102-011-0361-9","volume":"15","author":"E Couture","year":"2012","unstructured":"Couture E, Bongard V, Maiza JC, Bennet A, Caron P (2012) Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog Lanreotide. Pituitary 15(4):518\u2013525","journal-title":"Pituitary"},{"key":"2589_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/B978-0-12-800174-5.00007-7","volume":"95","author":"M Braun","year":"2014","unstructured":"Braun M (2014) The somatostatin receptor in human pancreatic beta-cells. Vitam Horm 95:165\u2013193","journal-title":"Vitam Horm"},{"issue":"12","key":"2589_CR29","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1210\/jc.2005-0901","volume":"90","author":"RA Feelders","year":"2005","unstructured":"Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ et al (2005) Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 90(12):6480\u20136489","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2589_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/jdi.12675","volume":"9","author":"S Tanaka","year":"2018","unstructured":"Tanaka S, Haketa A, Yamamuro S, Suzuki T, Kobayashi H, Hatanaka Y et al (2018) Marked alteration of glycemic profile surrounding Lanreotide administration in acromegaly: A case report. J Diabetes Investig 9(1):223\u2013225","journal-title":"J Diabetes Investig"},{"issue":"12","key":"2589_CR31","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I et al (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9(12):1178\u20131190","journal-title":"Endocr Connect"},{"key":"2589_CR32","doi-asserted-by":"publisher","first-page":"1348990","DOI":"10.3389\/fendo.2024.1348990","volume":"15","author":"S Stormann","year":"2024","unstructured":"Stormann S, Meyhofer SM, Groener JB, Faust J, Schilbach K, Seufert J et al (2024) Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts\u2019 consensus statement. Front Endocrinol (Lausanne) 15:1348990","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2589_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S1096-6374(02)00083-7","volume":"12","author":"DR Rose","year":"2002","unstructured":"Rose DR, Clemmons DR (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 12(6):418\u2013424","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"2589_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11102-015-0691-0","volume":"19","author":"I Bernabeu","year":"2016","unstructured":"Bernabeu I, Pico A, Venegas E, Aller J, Alvarez-Escola C, Garcia-Arnes JA et al (2016) Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19(2):127\u2013137","journal-title":"Pituitary"},{"issue":"3","key":"2589_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","volume":"63","author":"T Brue","year":"2019","unstructured":"Brue T, Lindberg A, van der Jan A, Akerblad AC, Koltowska-Haggstrom M, Gomez R et al (2019) Diabetes in patients with acromegaly treated with Pegvisomant: observations from acrostudy. Endocrine 63(3):563\u2013572","journal-title":"Endocrine"},{"issue":"2","key":"2589_CR36","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen J et al (2018) Efficacy and safety of switching to Pasireotide in patients with acromegaly controlled with Pegvisomant and First-Generation somatostatin analogues (PAPE Study). J Clin Endocrinol Metab 103(2):586\u2013595","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2589_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12020-023-03525-1","volume":"83","author":"M Vranic","year":"2024","unstructured":"Vranic M, Ahmed F, Kristofi R, Hetty S, Mokhtari D, Svensson MK et al (2024) Subcutaneous adipose tissue dopamine D2 receptor is increased in prediabetes and T2D. Endocrine 83(2):378\u2013391","journal-title":"Endocrine"},{"issue":"9","key":"2589_CR38","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41380-018-0344-6","volume":"25","author":"ZJ Farino","year":"2020","unstructured":"Farino ZJ, Morgenstern TJ, Maffei A, Quick M, De Solis AJ, Wiriyasermkul P et al (2020) New roles for dopamine D(2) and D(3) receptors in pancreatic beta cell insulin secretion. Mol Psychiatry 25(9):2070\u20132085","journal-title":"Mol Psychiatry"},{"key":"2589_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2015.12.029","volume":"109","author":"F Lopez Vicchi","year":"2016","unstructured":"Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D (2016) Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res 109:74\u201380","journal-title":"Pharmacol Res"},{"issue":"5","key":"2589_CR40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ghir.2010.05.004","volume":"20","author":"J Roemmler","year":"2010","unstructured":"Roemmler J, Steffin B, Gutt B, Schneider HJ, Sievers C, Bidlingmaier M et al (2010) The acute effect of a single application of Cabergoline on endogenous GH levels in patients with acromegaly on Pegvisomant treatment. Growth Horm IGF Res 20(5):338\u2013344","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"2589_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/BF00186626","volume":"71","author":"H Rau","year":"1993","unstructured":"Rau H, Althoff PH, Schmidt K, Badenhoop K, Usadel KH (1993) Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion. Clin Investig 71(5):372\u2013378","journal-title":"Clin Investig"},{"issue":"2","key":"2589_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4103\/0975-7406.67000","volume":"2","author":"Y Keche","year":"2010","unstructured":"Keche Y (2010) Bromocriptine mesylate: food and drug administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control. J Pharm Bioallied Sci 2(2):148\u2013150","journal-title":"J Pharm Bioallied Sci"},{"issue":"8","key":"2589_CR43","doi-asserted-by":"publisher","first-page":"104771","DOI":"10.1016\/j.isci.2022.104771","volume":"25","author":"D Aslanoglou","year":"2022","unstructured":"Aslanoglou D, Bertera S, Friggeri L, Sanchez-Soto M, Lee J, Xue X et al (2022) Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of Bromocriptine. iScience 25(8):104771","journal-title":"iScience"},{"key":"2589_CR44","doi-asserted-by":"publisher","first-page":"101241","DOI":"10.1016\/j.molmet.2021.101241","volume":"51","author":"G Tavares","year":"2021","unstructured":"Tavares G, Marques D, Barra C, Rosendo-Silva D, Costa A, Rodrigues T et al (2021) Dopamine D2 receptor agonist, Bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes. Mol Metab 51:101241","journal-title":"Mol Metab"},{"key":"2589_CR45","unstructured":"Valea A, Carsote M, Ghervan C, Georgescu C (2015) Glycemic profile in patients with acromegaly treated with somatostatin analogue. J Med Life. 8 Spec Issue(Spec Issue):82\u2013\u20096."},{"issue":"9","key":"2589_CR46","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1172\/JCI200316575","volume":"111","author":"AP Heaney","year":"2003","unstructured":"Heaney AP, Fernando M, Melmed S (2003) PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111(9):1381\u20131388","journal-title":"J Clin Invest"},{"issue":"6","key":"2589_CR47","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22(6):724\u2013763","journal-title":"Endocr Rev"},{"key":"2589_CR48","doi-asserted-by":"crossref","unstructured":"Guarnotta V, Amodei R, Di Gaudio F, Giordano C (2023) Nutritional Intervention in Cushing\u2019s Disease: The Ketogenic Diet\u2019s Effects on Metabolic Comorbidities and Adrenal Steroids. Nutrients. 15(21):4647.","DOI":"10.3390\/nu15214647"},{"issue":"1","key":"2589_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12020-022-03168-8","volume":"79","author":"M Moustaki","year":"2023","unstructured":"Moustaki M, Paschou SA, Vakali EC, Vryonidou A (2023) Secondary diabetes mellitus due to primary aldosteronism. Endocrine 79(1):17\u201330","journal-title":"Endocrine"},{"issue":"9","key":"2589_CR50","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41574-024-00993-x","volume":"20","author":"D Esposito","year":"2024","unstructured":"Esposito D, Boguszewski CL, Colao A, Fleseriu M, Gatto F, Jorgensen JOL et al (2024) Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol 20(9):541\u2013552","journal-title":"Nat Rev Endocrinol"},{"key":"2589_CR51","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3389\/fendo.2019.00509","volume":"10","author":"G Vila","year":"2019","unstructured":"Vila G, Jorgensen JOL, Luger A, Stalla GK (2019) Insulin resistance in patients with acromegaly. Front Endocrinol (Lausanne) 10:509","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2589_CR52","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr., Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2589_CR53","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"L Blonde","year":"2022","unstructured":"Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M et al (2022) American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care Plan-2022 update. Endocr Pract 28(10):923\u20131049","journal-title":"Endocr Pract"},{"issue":"8","key":"2589_CR54","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1210\/jc.2015-1917","volume":"100","author":"CM Reyes-Vidal","year":"2015","unstructured":"Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC et al (2015) Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab 100(8):2946\u20132955","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2589_CR55","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/jc.2017-01210","volume":"102","author":"MA Bredella","year":"2017","unstructured":"Bredella MA, Schorr M, Dichtel LE, Gerweck AV, Young BJ, Woodmansee WW et al (2017) Body composition and ectopic lipid changes with biochemical control of acromegaly. J Clin Endocrinol Metab 102(11):4218\u20134225","journal-title":"J Clin Endocrinol Metab"},{"key":"2589_CR56","doi-asserted-by":"crossref","unstructured":"Derrick SA, Nguyen ST, Marthens JR, Dambacher LL, Sikalidis AK, Reaves SK (2023) A Mediterranean-Style diet improves the parameters for the management and prevention of type 2 diabetes mellitus. Med (Kaunas). 59(10):1882.","DOI":"10.3390\/medicina59101882"},{"key":"2589_CR57","doi-asserted-by":"crossref","unstructured":"Singh RB, Fedacko J, Fatima G, Magomedova A, Watanabe S, Elkilany G (2022) Why and how the Indo-Mediterranean diet May be superior to other diets: the role of antioxidants in the diet. Nutrients. 14(4):898.","DOI":"10.3390\/nu14040898"},{"key":"2589_CR58","doi-asserted-by":"crossref","unstructured":"Carbone JW, Pasiakos SM (2019) Dietary protein and muscle mass: translating science to application and health benefit. Nutrients. 11(5):1136.","DOI":"10.3390\/nu11051136"},{"issue":"11","key":"2589_CR59","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40618-019-01061-2","volume":"42","author":"M Caprio","year":"2019","unstructured":"Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G et al (2019) Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian society of endocrinology (SIE). J Endocrinol Invest 42(11):1365\u20131386","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2589_CR60","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40618-023-02258-2","volume":"47","author":"L Barrea","year":"2024","unstructured":"Barrea L, Caprio M, Camajani E, Verde L, Perrini S, Cignarelli A et al (2024) Ketogenic nutritional therapy (KeNuT)-a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the club of the Italian society of endocrinology (SIE)-diet therapies in endocrinology and metabolism. J Endocrinol Invest 47(3):487\u2013500","journal-title":"J Endocrinol Invest"},{"issue":"22","key":"2589_CR61","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMc1915808","volume":"382","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, Berk KAC, El-Sayed N, Neggers S, van der Lely AJ (2020) Eucaloric Very-Low-Carbohydrate ketogenic diet in acromegaly treatment. N Engl J Med 382(22):2161\u20132162","journal-title":"N Engl J Med"},{"issue":"2","key":"2589_CR62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jama.2023.11305","volume":"330","author":"M Reincke","year":"2023","unstructured":"Reincke M, Fleseriu M, Cushing Syndrome (2023) Rev JAMA 330(2):170\u2013181","journal-title":"Rev JAMA"},{"issue":"9","key":"2589_CR63","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"JX Li","year":"2022","unstructured":"Li JX, Cummins CL (2022) Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 18(9):540\u2013557","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2589_CR64","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/MED.0000000000000537","volume":"27","author":"A Sharma","year":"2020","unstructured":"Sharma A, Vella A (2020) Glucose metabolism in Cushing\u2019s syndrome. Curr Opin Endocrinol Diabetes Obes 27(3):140\u2013145","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2589_CR65","doi-asserted-by":"crossref","unstructured":"Feraco A, Gorini S, Armani A, Camajani E, Rizzo M, Caprio M (2021) Exploring the role of skeletal muscle in insulin resistance: lessons from cultured cells to animal models. Int J Mol Sci. 22(17):9327.","DOI":"10.3390\/ijms22179327"},{"issue":"10","key":"2589_CR66","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1096\/fj.201601125RRR","volume":"31","author":"A Armani","year":"2017","unstructured":"Armani A, Berry A, Cirulli F, Caprio M (2017) Molecular mechanisms underlying metabolic syndrome: the expanding role of the adipocyte. FASEB J 31(10):4240\u20134255","journal-title":"FASEB J"},{"issue":"12","key":"2589_CR67","doi-asserted-by":"publisher","first-page":"e15188","DOI":"10.1371\/journal.pone.0015188","volume":"5","author":"CY Yu","year":"2010","unstructured":"Yu CY, Mayba O, Lee JV, Tran J, Harris C, Speed TP et al (2010) Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. PLoS ONE 5(12):e15188","journal-title":"PLoS ONE"},{"key":"2589_CR68","doi-asserted-by":"crossref","unstructured":"Beaupere C, Liboz A, Feve B, Blondeau B, Guillemain G (2021) Molecular mechanisms of Glucocorticoid-Induced insulin resistance. Int J Mol Sci. 22(2):623.","DOI":"10.3390\/ijms22020623"},{"key":"2589_CR69","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3389\/fphar.2020.00429","volume":"11","author":"F Diaz-Castro","year":"2020","unstructured":"Diaz-Castro F, Monsalves-Alvarez M, Rojo LE, Del Campo A, Troncoso R (2020) Mifepristone for treatment of metabolic syndrome: beyond Cushing\u2019s syndrome. Front Pharmacol 11:429","journal-title":"Front Pharmacol"},{"issue":"2","key":"2589_CR70","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0584","volume":"220","author":"S Guo","year":"2014","unstructured":"Guo S (2014) Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol 220(2):T1\u2013T23","journal-title":"J Endocrinol"},{"issue":"3","key":"2589_CR71","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1445-5994.2007.01434.x","volume":"38","author":"S Newsome","year":"2008","unstructured":"Newsome S, Chen K, Hoang J, Wilson JD, Potter JM, Hickman PE (2008) Cushing\u2019s syndrome in a clinic population with diabetes. Intern Med J 38(3):178\u2013182","journal-title":"Intern Med J"},{"issue":"10","key":"2589_CR72","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41574-020-0381-5","volume":"16","author":"F Magkos","year":"2020","unstructured":"Magkos F, Hjorth MF, Astrup A (2020) Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16(10):545\u2013555","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2589_CR73","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s13668-024-00560-w","volume":"13","author":"L Barrea","year":"2024","unstructured":"Barrea L, Caprio M, Grassi D, Cicero AFG, Bagnato C, Paolini B et al (2024) A new nomenclature for the very Low-Calorie ketogenic diet (VLCKD): very Low-Energy ketogenic therapy (VLEKT). Ketodiets and nutraceuticals expert panels: KetoNut, Italian society of nutraceuticals (SINut) and the Italian association of dietetics and clinical nutrition (ADI). Curr Nutr Rep 13(3):552\u2013556","journal-title":"Curr Nutr Rep"},{"key":"2589_CR74","doi-asserted-by":"crossref","unstructured":"Polito R, Messina G, Valenzano A, Scarinci A, Villano I, Monda M et al (2021) The role of very low calorie ketogenic diet in sympathetic activation through cortisol secretion in male obese population. J Clin Med. 10(18):4230.","DOI":"10.3390\/jcm10184230"},{"issue":"21","key":"2589_CR75","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1056\/NEJM196511182732106","volume":"273","author":"JW Conn","year":"1965","unstructured":"Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273(21):1135\u20131143","journal-title":"N Engl J Med"},{"issue":"5","key":"2589_CR76","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1530\/EJE-15-0450","volume":"173","author":"G Hanslik","year":"2015","unstructured":"Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B et al (2015) Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn\u2019s registry. Eur J Endocrinol 173(5):665\u2013675","journal-title":"Eur J Endocrinol"},{"key":"2589_CR77","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","volume":"91","author":"JM Luther","year":"2014","unstructured":"Luther JM (2014) Effects of aldosterone on insulin sensitivity and secretion. Steroids 91:54\u201360","journal-title":"Steroids"},{"issue":"10","key":"2589_CR78","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.cellsig.2011.05.022","volume":"23","author":"TT Chiu","year":"2011","unstructured":"Chiu TT, Jensen TE, Sylow L, Richter EA, Klip A (2011) Rac1 signalling towards GLUT4\/glucose uptake in skeletal muscle. Cell Signal 23(10):1546\u20131554","journal-title":"Cell Signal"},{"issue":"4","key":"2589_CR79","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/j.2040-4603.2017.tb00777.x","volume":"7","author":"M Infante","year":"2017","unstructured":"Infante M, Armani A, Mammi C, Fabbri A, Caprio M (2017) Impact of adrenal steroids on regulation of adipose tissue. Compr Physiol 7(4):1425\u20131447","journal-title":"Compr Physiol"},{"issue":"2","key":"2589_CR80","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M et al (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91(2):454\u2013459","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2589_CR81","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","volume":"54","author":"JM Luther","year":"2011","unstructured":"Luther JM, Luo P, Kreger MT, Brissova M, Dai C, Whitfield TT et al (2011) Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine Islets. Diabetologia 54(8):2152\u20132163","journal-title":"Diabetologia"},{"issue":"3","key":"2589_CR82","doi-asserted-by":"publisher","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","volume":"326","author":"S Verma","year":"2024","unstructured":"Verma S, Pandey A, Pandey AK, Butler J, Lee JS, Teoh H et al (2024) Aldosterone and aldosterone synthase inhibitors in cardiorenal disease. Am J Physiol Heart Circ Physiol 326(3):H670\u2013H88","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2589_CR83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJM200101043440101","volume":"344","author":"FM Sacks","year":"2001","unstructured":"Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D et al (2001) Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium collaborative research group. N Engl J Med 344(1):3\u201310","journal-title":"N Engl J Med"},{"issue":"3","key":"2589_CR84","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1370\/afm.2968","volume":"21","author":"LR Saslow","year":"2023","unstructured":"Saslow LR, Jones LM, Sen A, Wolfson JA, Diez HL, O\u2019Brien A et al (2023) Comparing very Low-Carbohydrate vs DASH diets for overweight or obese adults with hypertension and prediabetes or type 2 diabetes: A randomized trial. Ann Fam Med 21(3):256\u2013263","journal-title":"Ann Fam Med"},{"issue":"10","key":"2589_CR85","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1161\/CIRCULATIONAHA.116.024545","volume":"135","author":"FZ Marques","year":"2017","unstructured":"Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M et al (2017) High-Fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135(10):964\u2013977","journal-title":"Circulation"},{"key":"2589_CR86","doi-asserted-by":"crossref","unstructured":"Clemente-Suarez VJ, Mielgo-Ayuso J, Martin-Rodriguez A, Ramos-Campo DJ, Redondo-Florez L, Tornero-Aguilera JF (2022) The burden of carbohydrates in health and disease. Nutrients. 14(18):3809.","DOI":"10.3390\/nu14183809"},{"key":"2589_CR87","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1196\/annals.1410.081","volume":"1148","author":"V Kantorovich","year":"2008","unstructured":"Kantorovich V, Eisenhofer G, Pacak K (2008) Pheochromocytoma: an endocrine stress mimicking disorder. Ann N Y Acad Sci 1148:462\u2013468","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"2589_CR88","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.dsx.2020.10.030","volume":"14","author":"S Khatiwada","year":"2020","unstructured":"Khatiwada S, Agarwal S, Kandasamy D, Jyotsna VP, Kumar R, Kumar Bansal V et al (2020) Diabetes mellitus in pheochromocytoma and paraganglioma: prevalence, dynamics of insulin secretion \/ sensitivity and predictors of remission. Diabetes Metab Syndr 14(6):2169\u20132175","journal-title":"Diabetes Metab Syndr"},{"issue":"8","key":"2589_CR89","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","volume":"38","author":"JWM Lenders","year":"2020","unstructured":"Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D et al (2020) Genetics, diagnosis, management and future directions of research of Phaeochromocytoma and paraganglioma: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens 38(8):1443\u20131456","journal-title":"J Hypertens"},{"issue":"2","key":"2589_CR90","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1507\/endocrj.EJ18-0407","volume":"66","author":"I Abe","year":"2019","unstructured":"Abe I, Fujii H, Ohishi H, Sugimoto K, Minezaki M, Nakagawa M et al (2019) Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma. Endocr J 66(2):187\u2013192","journal-title":"Endocr J"},{"issue":"2","key":"2589_CR91","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00210-003-0858-5","volume":"369","author":"E Vieira","year":"2004","unstructured":"Vieira E, Liu YJ, Gylfe E (2004) Involvement of alpha1 and beta-adrenoceptors in adrenaline stimulation of the glucagon-secreting mouse alpha-cell. Naunyn Schmiedebergs Arch Pharmacol 369(2):179\u2013183","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2589_CR92","first-page":"45","volume":"15","author":"MM Adeva-Andany","year":"2019","unstructured":"Adeva-Andany MM, Funcasta-Calderon R, Fernandez-Fernandez C, Castro-Quintela E, Carneiro-Freire N (2019) Metabolic effects of glucagon in humans. J Clin Transl Endocrinol 15:45\u201353","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"2589_CR93","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/oby.2002.75","volume":"10","author":"M Boschmann","year":"2002","unstructured":"Boschmann M, Krupp G, Luft FC, Klaus S, Jordan J (2002) In vivo response to alpha(1)-adrenoreceptor stimulation in human white adipose tissue. Obes Res 10(6):555\u2013558","journal-title":"Obes Res"},{"issue":"14","key":"2589_CR94","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2174\/1381612013397339","volume":"7","author":"CJ de Souza","year":"2001","unstructured":"de Souza CJ, Burkey BF (2001) Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des 7(14):1433\u20131449","journal-title":"Curr Pharm Des"},{"key":"2589_CR95","doi-asserted-by":"publisher","first-page":"593780","DOI":"10.3389\/fendo.2020.593780","volume":"11","author":"I Abe","year":"2020","unstructured":"Abe I, Islam F, Lam AK (2020) Glucose intolerance on Phaeochromocytoma and Paraganglioma-The current Understanding and clinical perspectives. Front Endocrinol (Lausanne) 11:593780","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2589_CR96","doi-asserted-by":"crossref","unstructured":"Lopez C, Bima C, Bollati M, Bioletto F, Procopio M, Arata S et al (2023) Pathophysiology and management of glycemic alterations before and after surgery for pheochromocytoma and paraganglioma. Int J Mol Sci. 24(6):5153.","DOI":"10.3390\/ijms24065153"},{"issue":"1","key":"2589_CR97","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14310\/horm.2002.1184","volume":"2","author":"E Diamanti-Kandarakis","year":"2003","unstructured":"Diamanti-Kandarakis E, Zapanti E, Peridis MH, Ntavos P, Mastorakos G (2003) Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. Horm (Athens) 2(1):61\u201366","journal-title":"Horm (Athens)"},{"issue":"8","key":"2589_CR98","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1530\/EC-21-0269","volume":"10","author":"I Folling","year":"2021","unstructured":"Folling I, Wennerstrom AB, Eide TJ, Nilsen HL (2021) Phaeochromocytomas overexpress insulin transcript and produce insulin. Endocr Connect 10(8):815\u2013824","journal-title":"Endocr Connect"},{"issue":"12","key":"2589_CR99","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O\u2019Kane","year":"2019","unstructured":"O\u2019Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ et al (2019) A phase 2 trial of Sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer 120(12):1113\u20131119","journal-title":"Br J Cancer"},{"issue":"5","key":"2589_CR100","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2337\/dci22-0047","volume":"46","author":"OHY Yu","year":"2023","unstructured":"Yu OHY, Suissa S (2023) Metformin and cancer: solutions to a Real-World evidence failure. Diabetes Care 46(5):904\u2013912","journal-title":"Diabetes Care"},{"issue":"2","key":"2589_CR101","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7326\/0003-4819-71-2-251","volume":"71","author":"JA Colwell","year":"1969","unstructured":"Colwell JA (1969) Inhibition of insulin secretion by catecholamines in pheochromocytoma. Ann Intern Med 71(2):251\u2013256","journal-title":"Ann Intern Med"},{"issue":"3","key":"2589_CR102","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2337\/db16-1166","volume":"66","author":"K Ito","year":"2017","unstructured":"Ito K, Dezaki K, Yoshida M, Yamada H, Miura R, Rita RS et al (2017) Endogenous alpha2A-Adrenoceptor-Operated sympathoadrenergic tones attenuate insulin secretion via cAMP\/TRPM2 signaling. Diabetes 66(3):699\u2013709","journal-title":"Diabetes"},{"key":"2589_CR103","doi-asserted-by":"crossref","unstructured":"Petrak O, Klimova J, Mraz M, Haluzikova D, Dolezalova RP, Kratochvilova H et al (2020) Pheochromocytoma with adrenergic biochemical phenotype shows decreased GLP-1 secretion and impaired glucose tolerance. J Clin Endocrinol Metab. 105(6):dgaa154.","DOI":"10.1210\/clinem\/dgaa154"},{"issue":"2","key":"2589_CR104","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D et al (2023) GLP-1 receptor agonists and the risk of thyroid Cancer. Diabetes Care 46(2):384\u2013390","journal-title":"Diabetes Care"},{"key":"2589_CR105","doi-asserted-by":"publisher","first-page":"173141","DOI":"10.1016\/j.ejphar.2020.173141","volume":"879","author":"EC So","year":"2020","unstructured":"So EC, Liu PY, Wu SN (2020) Effectiveness in the Inhibition of Dapagliflozin and Canagliflozin on M-type K(+) current and alpha-methylglucoside-induced current in pituitary tumor (GH(3)) and pheochromocytoma PC12 cells. Eur J Pharmacol 879:173141","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"2589_CR106","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2215\/CJN.17621120","volume":"16","author":"BF Palmer","year":"2021","unstructured":"Palmer BF, Clegg DJ (2021) Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol 16(8):1284\u20131291","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2589_CR107","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1172\/JCI111253","volume":"73","author":"RA DeFronzo","year":"1984","unstructured":"DeFronzo RA, Thorin D, Felber JP, Simonson DC, Thiebaud D, Jequier E et al (1984) Effect of beta and alpha adrenergic Blockade on glucose-induced thermogenesis in man. J Clin Invest 73(3):633\u2013639","journal-title":"J Clin Invest"},{"issue":"1","key":"2589_CR108","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ando.2020.01.001","volume":"81","author":"A Elenkova","year":"2020","unstructured":"Elenkova A, Matrozova J, Vasilev V, Robeva R, Zacharieva S (2020) Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma\/paraganglioma: retrospective single-center study. Ann Endocrinol (Paris) 81(1):3\u201310","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"2589_CR109","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3803\/EnM.2021.1251","volume":"36","author":"E Song","year":"2021","unstructured":"Song E, Koo MJ, Noh E, Hwang SY, Park MJ, Kim JA et al (2021) Risk of diabetes in patients with Long-Standing graves\u2019 disease: A longitudinal study. Endocrinol Metab (Seoul) 36(6):1277\u20131286","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"6","key":"2589_CR110","doi-asserted-by":"publisher","first-page":"e66711","DOI":"10.1371\/journal.pone.0066711","volume":"8","author":"F Brandt","year":"2013","unstructured":"Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L et al (2013) Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS ONE 8(6):e66711","journal-title":"PLoS ONE"},{"issue":"5","key":"2589_CR111","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1530\/EJE-22-0523","volume":"187","author":"H Alwan","year":"2022","unstructured":"Alwan H, Villoz F, Feller M, Dullaart RPF, Bakker SJL, Peeters RP et al (2022) Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies. Eur J Endocrinol 187(5):S35\u2013S46","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2589_CR112","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/EJE-10-0246","volume":"163","author":"E Maratou","year":"2010","unstructured":"Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, Lambadiari V et al (2010) Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur J Endocrinol 163(4):625\u2013630","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2589_CR113","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/0026-0495(90)90031-7","volume":"39","author":"T Ikeda","year":"1990","unstructured":"Ikeda T, Fujiyama K, Hoshino T, Takeuchi T, Mashiba H, Tominaga M (1990) Oral and intravenous glucose-induced insulin secretion in hyperthyroid patients. Metabolism 39(6):633\u2013637","journal-title":"Metabolism"},{"issue":"4","key":"2589_CR114","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1210\/jcem-70-4-1167","volume":"70","author":"MC Foss","year":"1990","unstructured":"Foss MC, Paccola GM, Saad MJ, Pimenta WP, Piccinato CE, Iazigi N (1990) Peripheral glucose metabolism in human hyperthyroidism. J Clin Endocrinol Metab 70(4):1167\u20131172","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2589_CR115","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12020-018-1820-0","volume":"64","author":"G Gao","year":"2019","unstructured":"Gao G, Li FF, Hu Y, Yan RN, Liu BL, Liu XM et al (2019) Glycemic variation in uncontrolled graves\u2019 disease patients with normal glucose metabolism: assessment by continuous glucose monitoring. Endocrine 64(2):265\u2013270","journal-title":"Endocrine"},{"issue":"6","key":"2589_CR116","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1210\/jcem-61-6-1165","volume":"61","author":"JP Randin","year":"1985","unstructured":"Randin JP, Scazziga B, Jequier E, Felber JP (1985) Study of glucose and lipid metabolism by continuous indirect calorimetry in graves\u2019 disease: effect of an oral glucose load. J Clin Endocrinol Metab 61(6):1165\u20131171","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2589_CR117","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1046\/j.1365-2265.1996.636458.x","volume":"44","author":"K Bech","year":"1996","unstructured":"Bech K, Damsbo P, Eldrup E, Beck-Nielsen H, Roder ME, Hartling SG et al (1996) beta-cell function and glucose and lipid oxidation in graves\u2019 disease. Clin Endocrinol (Oxf) 44(1):59\u201366","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2589_CR118","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1210\/jcem-51-3-478","volume":"51","author":"UM Kabadi","year":"1980","unstructured":"Kabadi UM, Eisenstein AB (1980) Impaired pancreatic alpha-cell response in hyperthyroidism. J Clin Endocrinol Metab 51(3):478\u2013482","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2589_CR119","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4158\/EP.12.2.121","volume":"12","author":"KA Al-Shoumer","year":"2006","unstructured":"Al-Shoumer KA, Vasanthy BA, Al-Zaid MM (2006) Effects of treatment of hyperthyroidism on glucose homeostasis, insulin secretion, and markers of bone turnover. Endocr Pract 12(2):121\u2013130","journal-title":"Endocr Pract"},{"issue":"6","key":"2589_CR120","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1210\/jc.2007-2832","volume":"93","author":"G Dimitriadis","year":"2008","unstructured":"Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Koukkou E et al (2008) Insulin-stimulated rates of glucose uptake in muscle in hyperthyroidism: the importance of blood flow. J Clin Endocrinol Metab 93(6):2413\u20132415","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2589_CR121","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2265.1996.8500860.x","volume":"45","author":"MA Gonzalo","year":"1996","unstructured":"Gonzalo MA, Grant C, Moreno I, Garcia FJ, Suarez AI, Herrera-Pombo JL et al (1996) Glucose tolerance, insulin secretion, insulin sensitivity and glucose effectiveness in normal and overweight hyperthyroid women. Clin Endocrinol (Oxf) 45(6):689\u2013697","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2589_CR122","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/2230-8210.196017","volume":"21","author":"R Bhattacharjee","year":"2017","unstructured":"Bhattacharjee R, Thukral A, Chakraborty PP, Roy A, Goswami S, Ghosh S et al (2017) Effects of thyroid status on glycated hemoglobin. Indian J Endocrinol Metab 21(1):26\u201330","journal-title":"Indian J Endocrinol Metab"},{"issue":"2","key":"2589_CR123","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1432-1033.1970.tb00925.x","volume":"13","author":"I Bottger","year":"1970","unstructured":"Bottger I, Kriegel H, Wieland O (1970) Fluctuation of hepatic enzymes important in glucose metabolism in relation to thyroid function. Eur J Biochem 13(2):253\u2013257","journal-title":"Eur J Biochem"},{"issue":"3","key":"2589_CR124","doi-asserted-by":"crossref","first-page":"45P","DOI":"10.1042\/bj1040045C","volume":"104","author":"RA Freedland","year":"1967","unstructured":"Freedland RA, Krebs HA (1967) The effect of thyroxine treatment on the rate of gluconeogenesis in the perfused rat liver. Biochem J 104(3):45P","journal-title":"Biochem J"},{"issue":"2","key":"2589_CR125","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1042\/bj1820565","volume":"182","author":"F Okajima","year":"1979","unstructured":"Okajima F, Ui M (1979) Metabolism of glucose in hyper- and hypo-thyroid rats in vivo. Glucose-turnover values and futile-cycle activities obtained with 14\u00a0C- and 3H-labelled glucose. Biochem J 182(2):565\u2013575","journal-title":"Biochem J"},{"issue":"1","key":"2589_CR126","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1042\/bj1960247","volume":"196","author":"ME Laker","year":"1981","unstructured":"Laker ME, Mayes PA (1981) Effect of hyperthyroidism and hypothyroidism on lipid and carbohydrate metabolism of the perfused rat liver. Biochem J 196(1):247\u2013255","journal-title":"Biochem J"},{"issue":"2","key":"2589_CR127","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1210\/endo.135.2.8033812","volume":"135","author":"SP Weinstein","year":"1994","unstructured":"Weinstein SP, O\u2019Boyle E, Fisher M, Haber RS (1994) Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. Endocrinology 135(2):649\u2013654","journal-title":"Endocrinology"},{"issue":"2","key":"2589_CR128","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1677\/joe.0.1600285","volume":"160","author":"T Mokuno","year":"1999","unstructured":"Mokuno T, Uchimura K, Hayashi R, Hayakawa N, Makino M, Nagata M et al (1999) Glucose transporter 2 concentrations in hyper- and hypothyroid rat livers. J Endocrinol 160(2):285\u2013289","journal-title":"J Endocrinol"},{"key":"2589_CR129","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/0026-0495(64)90068-X","volume":"13","author":"ES Gordon","year":"1964","unstructured":"Gordon ES, Goldberg M (1964) Carbon-14 studies of energy metabolism in various thyroid States. Metabolism 13:591\u2013608","journal-title":"Metabolism"},{"issue":"1\u20132","key":"2589_CR130","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0303-7207(97)04026-4","volume":"128","author":"HF Kemp","year":"1997","unstructured":"Kemp HF, Hundal HS, Taylor PM (1997) Glucose transport correlates with GLUT2 abundance in rat liver during altered thyroid status. Mol Cell Endocrinol 128(1\u20132):97\u2013102","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2589_CR131","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2337\/diab.35.2.178","volume":"35","author":"JP Randin","year":"1986","unstructured":"Randin JP, Tappy L, Scazziga B, Jequier E, Felber JP (1986) Insulin sensitivity and exogenous insulin clearance in graves\u2019 disease. Measurement by the glucose clamp technique and continuous indirect calorimetry. Diabetes 35(2):178\u2013181","journal-title":"Diabetes"},{"issue":"3","key":"2589_CR132","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0016-5085(49)80129-6","volume":"12","author":"TL Althausen","year":"1949","unstructured":"Althausen TL (1949) Hormonal and vitamin factors in intestinal absorption. Gastroenterology 12(3):467\u2013480","journal-title":"Gastroenterology"},{"issue":"2","key":"2589_CR133","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1136\/gut.6.2.200","volume":"6","author":"AJ Matty","year":"1965","unstructured":"Matty AJ, Seshadri B (1965) Effect of thyroxine on the isolated rat intestine. Gut 6(2):200\u2013202","journal-title":"Gut"},{"issue":"4","key":"2589_CR134","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1113\/jphysiol.1963.sp007294","volume":"169","author":"RJ Levin","year":"1963","unstructured":"Levin RJ, Smyth DH (1963) The effect of the thyroid gland on intestinal absorption of hexoses. J Physiol 169(4):755\u2013769","journal-title":"J Physiol"},{"issue":"1","key":"2589_CR135","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1172\/JCI101782","volume":"26","author":"V Moseley","year":"1947","unstructured":"Moseley V, Chornock FW (1947) Intubation studies of the human small intestine. Xxv. The absorption of galactose from the intestine.of normal individuals and thyrotoxic patients. J Clin Invest 26(1):11\u201317","journal-title":"J Clin Invest"},{"issue":"2","key":"2589_CR136","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1042\/bj2710421","volume":"271","author":"MC Sugden","year":"1990","unstructured":"Sugden MC, Liu YL, Holness MJ (1990) Glucose utilization by skeletal muscles in vivo in experimental hyperthyroidism in the rat. Biochem J 271(2):421\u2013425","journal-title":"Biochem J"},{"issue":"1","key":"2589_CR137","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0006-291X(90)91374-2","volume":"171","author":"A Casla","year":"1990","unstructured":"Casla A, Rovira A, Wells JA, Dohm GL (1990) Increased glucose transporter (GLUT4) protein expression in hyperthyroidism. Biochem Biophys Res Commun 171(1):182\u2013188","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"2589_CR138","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0024-3205(02)01791-5","volume":"71","author":"M Fukuchi","year":"2002","unstructured":"Fukuchi M, Shimabukuro M, Shimajiri Y, Oshiro Y, Higa M, Akamine H et al (2002) Evidence for a deficient pancreatic beta-cell response in a rat model of hyperthyroidism. Life Sci 71(9):1059\u20131070","journal-title":"Life Sci"},{"issue":"8","key":"2589_CR139","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1113\/EP085627","volume":"101","author":"N Karbalaei","year":"2016","unstructured":"Karbalaei N, Noorafshan A, Hoshmandi E (2016) Impaired glucose-stimulated insulin secretion and reduced beta-cell mass in pancreatic Islets of hyperthyroid rats. Exp Physiol 101(8):1114\u20131127","journal-title":"Exp Physiol"},{"issue":"5","key":"2589_CR140","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2169\/internalmedicine.34.339","volume":"34","author":"S Ohguni","year":"1995","unstructured":"Ohguni S, Notsu K, Kato Y (1995) Correlation of plasma free thyroxine levels with insulin sensitivity and metabolic clearance rate of insulin in patients with hyperthyroid graves\u2019 disease. Intern Med 34(5):339\u2013341","journal-title":"Intern Med"},{"issue":"1","key":"2589_CR141","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1210\/jcem-63-1-62","volume":"63","author":"MJ Muller","year":"1986","unstructured":"Muller MJ, von Schutz B, Huhnt HJ, Zick R, Mitzkat HJ, von zur Muhlen A (1986) Glucoregulatory function of thyroid hormones: interaction with insulin depends on the prevailing glucose concentration. J Clin Endocrinol Metab 63(1):62\u201371","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2589_CR142","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1055\/s-0028-1093418","volume":"10","author":"BL Wajchenberg","year":"1978","unstructured":"Wajchenberg BL, Cesar FP, Leme CE, Souza IT, Pieroni RR, Mattar E (1978) Carbohydrate metabolism in thyrotoxicosis: studies on insulin secretion before and after remission from the hyperthyroid state. Horm Metab Res 10(4):294\u2013299","journal-title":"Horm Metab Res"},{"issue":"2","key":"2589_CR143","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1042\/bj1820585","volume":"182","author":"F Okajima","year":"1979","unstructured":"Okajima F, Ui M (1979) Metabolism of glucose in hyper- and hypo-thyroid rats in vivo. Relation of catecholamine actions to thyroid activity in controlling glucose turnover. Biochem J 182(2):585\u2013592","journal-title":"Biochem J"},{"issue":"2","key":"2589_CR144","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2337\/diacare.8.2.161","volume":"8","author":"I Komiya","year":"1985","unstructured":"Komiya I, Yamada T, Sato A, Koizumi Y, Aoki T (1985) Effects of antithyroid drug therapy on blood glucose, serum insulin, and insulin binding to red blood cells in hyperthyroid patients of different ages. Diabetes Care 8(2):161\u2013168","journal-title":"Diabetes Care"},{"issue":"4","key":"2589_CR145","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1507\/endocrj.EJ13-0410","volume":"61","author":"K Torimoto","year":"2014","unstructured":"Torimoto K, Okada Y, Arao T, Mori H, Yamamoto S, Narisawa M et al (2014) Glucose variability before and after treatment of a patient with graves\u2019 disease complicated by diabetes mellitus: assessment by continuous glucose monitoring. Endocr J 61(4):321\u2013328","journal-title":"Endocr J"},{"issue":"9","key":"2589_CR146","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.0364-22","volume":"62","author":"A Kurozumi","year":"2023","unstructured":"Kurozumi A, Okada Y, Tanaka Y (2023) Changes in glucose intolerance after treatment with antithyroid drugs in patients with graves\u2019 disease using continuous glucose monitoring: A pilot study. Intern Med 62(9):1259\u20131263","journal-title":"Intern Med"},{"issue":"2","key":"2589_CR147","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000496924","volume":"8","author":"N Lakshmana Perumal","year":"2019","unstructured":"Lakshmana Perumal N, Selvi J, Sridharan K, Sahoo J, Kamalanathan S (2019) Insulin sensitivity and Beta-Cell function in graves\u2019 disease and their changes with the Carbimazole-Induced euthyroid state. Eur Thyroid J 8(2):59\u201363","journal-title":"Eur Thyroid J"},{"key":"2589_CR148","doi-asserted-by":"crossref","unstructured":"Wisnu W, Alwi I, Nafrialdi N, Pemayun TGD, Pantoro NI, Wijaya CN et al (2024) The effects of Anti-thyroid drugs on lipoproteins and insulin resistance in graves\u2019 disease: A randomized clinical trial. J Lipid Atheroscler.13(3):358-370.","DOI":"10.12997\/jla.2024.13.3.358"},{"issue":"1","key":"2589_CR149","doi-asserted-by":"publisher","first-page":"e105751","DOI":"10.5812\/ijem.105751","volume":"19","author":"D Mani Deepthi","year":"2021","unstructured":"Mani Deepthi D, Vaikkakara S, Patil A, Ganta S, Sachan A, Raghavendra K et al (2021) Effect of correction of hyperthyroidism with Anti-thyroid drugs on the glycated hemoglobin in Non-diabetic patients with primary hyperthyroidism. Int J Endocrinol Metab 19(1):e105751","journal-title":"Int J Endocrinol Metab"},{"issue":"11","key":"2589_CR150","first-page":"4178","volume":"84","author":"C Spitzweg","year":"1999","unstructured":"Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE (1999) Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 84(11):4178\u20134184","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2589_CR151","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1210\/jcem.83.5.4839","volume":"83","author":"C Spitzweg","year":"1998","unstructured":"Spitzweg C, Joba W, Eisenmenger W, Heufelder AE (1998) Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 83(5):1746\u20131751","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2589_CR152","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1530\/eje.0.1410382","volume":"141","author":"L Vayre","year":"1999","unstructured":"Vayre L, Sabourin JC, Caillou B, Ducreux M, Schlumberger M, Bidart JM (1999) Immunohistochemical analysis of Na+\/I- symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol 141(4):382\u2013386","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2589_CR153","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice C","year":"2024","unstructured":"American Diabetes Association Professional Practice C (2024) 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2024. Diabetes Care 47(Suppl 1):S158\u2013S78","journal-title":"Diabetes Care"},{"issue":"8","key":"2589_CR154","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00592-023-02107-x","volume":"60","author":"E Mannucci","year":"2023","unstructured":"Mannucci E, Candido R, Monache LD, Gallo M, Giaccari A, Masini ML et al (2023) 2023 Update on Italian guidelines for the treatment of type 2 diabetes. Acta Diabetol 60(8):1119\u20131151","journal-title":"Acta Diabetol"},{"issue":"3","key":"2589_CR155","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000442821","volume":"25","author":"C Anil","year":"2016","unstructured":"Anil C, Kut A, Atesagaoglu B, Nar A, Bascil Tutuncu N, Gursoy A (2016) Metformin decreases thyroid volume and nodule size in subjects with insulin resistance: A preliminary study. Med Princ Pract 25(3):233\u2013236","journal-title":"Med Princ Pract"},{"issue":"8","key":"2589_CR156","doi-asserted-by":"publisher","first-page":"6295","DOI":"10.1007\/s13277-015-3315-4","volume":"36","author":"B Han","year":"2015","unstructured":"Han B, Cui H, Kang L, Zhang X, Jin Z, Lu L et al (2015) Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway. Tumour Biol 36(8):6295\u20136304","journal-title":"Tumour Biol"},{"issue":"1","key":"2589_CR157","doi-asserted-by":"publisher","first-page":"E143","DOI":"10.1210\/jc.2013-2965","volume":"99","author":"R Lupoli","year":"2014","unstructured":"Lupoli R, Di Minno A, Tortora A, Ambrosino P, Lupoli GA, Di Minno MN (2014) Effects of treatment with Metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab 99(1):E143\u2013E148","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2589_CR158","first-page":"297","volume":"4","author":"F Chiarelli","year":"2008","unstructured":"Chiarelli F, Di Marzio D (2008) Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag 4(2):297\u2013304","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"2589_CR159","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1541-7786.MCR-06-0278","volume":"5","author":"FS Chou","year":"2007","unstructured":"Chou FS, Wang PS, Kulp S, Pinzone JJ (2007) Effects of Thiazolidinediones on differentiation, proliferation, and apoptosis. Mol Cancer Res 5(6):523\u2013530","journal-title":"Mol Cancer Res"},{"issue":"3","key":"2589_CR160","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/er.2018-00163","volume":"40","author":"B Biondi","year":"2019","unstructured":"Biondi B, Kahaly GJ, Robertson RP (2019) Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocr Rev 40(3):789\u2013824","journal-title":"Endocr Rev"},{"issue":"11","key":"2589_CR161","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 45(11):2753\u20132786","journal-title":"Diabetes Care"},{"issue":"4","key":"2589_CR162","first-page":"e58553","volume":"16","author":"CN Paulsingh","year":"2024","unstructured":"Paulsingh CN, Riaz MF, Garg G, Umeano L, Iftikhar S, Alhaddad SF et al (2024) Exploring the impact of personalized nutritional approaches on metabolism and immunity: A systematic review of various nutrients and dietary patterns. Cureus 16(4):e58553","journal-title":"Cureus"},{"issue":"9","key":"2589_CR163","doi-asserted-by":"publisher","first-page":"e13486","DOI":"10.1111\/obr.13486","volume":"23","author":"K Pasmans","year":"2022","unstructured":"Pasmans K, Meex RCR, van Loon LJC, Blaak EE (2022) Nutritional strategies to attenuate postprandial glycemic response. Obes Rev 23(9):e13486","journal-title":"Obes Rev"},{"issue":"2","key":"2589_CR164","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4314\/ahs.v16i2.15","volume":"16","author":"CO Eleazu","year":"2016","unstructured":"Eleazu CO (2016) The concept of low glycemic index and glycemic load foods as panacea for type 2 diabetes mellitus; prospects, challenges and solutions. Afr Health Sci 16(2):468\u2013479","journal-title":"Afr Health Sci"},{"issue":"4","key":"2589_CR165","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.clnu.2020.10.032","volume":"40","author":"Y Xie","year":"2021","unstructured":"Xie Y, Gou L, Peng M, Zheng J, Chen L (2021) Effects of soluble fiber supplementation on glycemic control in adults with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr 40(4):1800\u20131810","journal-title":"Clin Nutr"},{"key":"2589_CR166","doi-asserted-by":"publisher","first-page":"1388986","DOI":"10.3389\/fnut.2024.1388986","volume":"11","author":"DK Layman","year":"2024","unstructured":"Layman DK (2024) Impacts of protein quantity and distribution on body composition. Front Nutr 11:1388986","journal-title":"Front Nutr"},{"issue":"6","key":"2589_CR167","doi-asserted-by":"publisher","first-page":"E1067","DOI":"10.1152\/ajpendo.00253.2004","volume":"288","author":"AL Riis","year":"2005","unstructured":"Riis AL, Jorgensen JO, Gjedde S, Norrelund H, Jurik AG, Nair KS et al (2005) Whole body and forearm substrate metabolism in hyperthyroidism: evidence of increased basal muscle protein breakdown. Am J Physiol Endocrinol Metab 288(6):E1067\u2013E1073","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2589_CR168","doi-asserted-by":"publisher","first-page":"1424912","DOI":"10.3389\/fnut.2024.1424912","volume":"11","author":"S Sheffield","year":"2024","unstructured":"Sheffield S, Fiorotto ML, Davis TA (2024) Nutritional importance of animal-sourced foods in a healthy diet. Front Nutr 11:1424912","journal-title":"Front Nutr"},{"key":"2589_CR169","doi-asserted-by":"crossref","unstructured":"Jimenez-Cortegana C, Iglesias P, Ribalta J, Vilarino-Garcia T, Montanez L, Arrieta F et al (2021) Nutrients and dietary approaches in patients with type 2 diabetes mellitus and cardiovascular disease: A narrative review. Nutrients. 13(11):4150.","DOI":"10.3390\/nu13114150"},{"issue":"2","key":"2589_CR170","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3803\/EnM.2023.1701","volume":"38","author":"AR Hong","year":"2023","unstructured":"Hong AR, Kang HC (2023) Evaluation and management of bone health in patients with thyroid diseases: A position statement of the Korean thyroid association. Endocrinol Metab (Seoul) 38(2):175\u2013189","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2589_CR171","doi-asserted-by":"crossref","unstructured":"Voulgaridou G, Papadopoulou SK, Detopoulou P, Tsoumana D, Giaginis C, Kondyli FS et al (2023) Vitamin D and calcium in osteoporosis, and the role of bone turnover markers: A narrative review of recent data from RCTs. Diseases. 11(1):29.","DOI":"10.3390\/diseases11010029"},{"key":"2589_CR172","doi-asserted-by":"crossref","unstructured":"Zavros A, Andreou E, Aphamis G, Bogdanis GC, Sakkas GK, Roupa Z et al (2023) The effects of zinc and selenium Co-Supplementation on resting metabolic rate, thyroid function, physical fitness, and functional capacity in overweight and obese people under a hypocaloric diet: A randomized, Double-Blind, and Placebo-Controlled trial. Nutrients. 15(14):3133","DOI":"10.3390\/nu15143133"},{"key":"2589_CR173","doi-asserted-by":"crossref","unstructured":"Chandrasekaran P, Weiskirchen R (2024) The role of obesity in type 2 diabetes Mellitus-An overview. Int J Mol Sci. 25(3):1882","DOI":"10.3390\/ijms25031882"},{"key":"2589_CR174","doi-asserted-by":"crossref","unstructured":"Minari TP, Tacito LHB, Yugar LBT, Ferreira-Melo SE, Manzano CF, Pires AC et al (2023) Nutritional strategies for the management of type 2 diabetes mellitus: A narrative review. Nutrients. 15(24):5096.","DOI":"10.3390\/nu15245096"},{"issue":"11","key":"2589_CR175","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2337\/dc16-1728","volume":"39","author":"SR Colberg","year":"2016","unstructured":"Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC et al (2016) Physical activity\/exercise and diabetes: A position statement of the American diabetes association. Diabetes Care 39(11):2065\u20132079","journal-title":"Diabetes Care"},{"issue":"9","key":"2589_CR176","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1089\/thy.2010.0396","volume":"21","author":"B Aschebrook-Kilfoy","year":"2011","unstructured":"Aschebrook-Kilfoy B, Sabra MM, Brenner A, Moore SC, Ron E, Schatzkin A et al (2011) Diabetes and thyroid cancer risk in the National institutes of health-AARP diet and health study. Thyroid 21(9):957\u2013963","journal-title":"Thyroid"},{"key":"2589_CR177","doi-asserted-by":"publisher","first-page":"103572","DOI":"10.1016\/j.critrevonc.2021.103572","volume":"169","author":"A Natalicchio","year":"2022","unstructured":"Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D\u2019Oronzo S, Marrano N et al (2022) Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): how do they influence each other? An Italian association of medical oncology (AIOM)\/ Italian association of medical diabetologists (AMD)\/ Italian society of endocrinology (SIE)\/ Italian society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 169:103572","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2589_CR178","first-page":"e46","volume":"6","author":"M Alvarez","year":"2020","unstructured":"Alvarez M, Almanzar A, Sanabria F, Meneses G, Velasquez L, Zarate L (2020) Manifestations of Glucagonoma syndrome. AACE Clin Case Rep 6(1):e46\u2013e9","journal-title":"AACE Clin Case Rep"},{"issue":"8","key":"2589_CR179","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland J, Falconi M, Christ E, Castano JP, Faggiano A, Lamarca A et al (2023) European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 35(8):e13318","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"2589_CR180","doi-asserted-by":"publisher","first-page":"E671","DOI":"10.1152\/ajpendo.00492.2002","volume":"284","author":"G Jiang","year":"2003","unstructured":"Jiang G, Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284(4):E671\u2013E678","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"2589_CR181","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4158\/EP15984.RA","volume":"22","author":"GR Kulina","year":"2016","unstructured":"Kulina GR, Rayfield EJ (2016) The role of glucagon in the pathophysiology and management of diabetes. Endocr Pract 22(5):612\u2013621","journal-title":"Endocr Pract"},{"issue":"3","key":"2589_CR182","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ejso.2007.07.209","volume":"34","author":"HL O\u2019Grady","year":"2008","unstructured":"O\u2019Grady HL, Conlon KC (2008) Pancreatic neuroendocrine tumours. Eur J Surg Oncol 34(3):324\u2013332","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"2589_CR183","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.cmet.2014.03.005","volume":"19","author":"WJ Song","year":"2014","unstructured":"Song WJ, Mondal P, Wolfe A, Alonso LC, Stamateris R, Ong BW et al (2014) Glucagon regulates hepatic Kisspeptin to impair insulin secretion. Cell Metab 19(4):667\u2013681","journal-title":"Cell Metab"},{"issue":"1","key":"2589_CR184","doi-asserted-by":"publisher","first-page":"17451","DOI":"10.1038\/s41598-019-53826-7","volume":"9","author":"C Huang","year":"2019","unstructured":"Huang C, Wang HY, Wang ME, Hsu MC, Wu YS, Jiang YF et al (2019) Kisspeptin-Activated autophagy independently suppresses Non-Glucose-Stimulated insulin secretion from pancreatic beta-Cells. Sci Rep 9(1):17451","journal-title":"Sci Rep"},{"issue":"3","key":"2589_CR185","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s005340050052","volume":"5","author":"J Soga","year":"1998","unstructured":"Soga J, Yakuwa Y (1998) Glucagonomas\/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg 5(3):312\u2013319","journal-title":"J Hepatobiliary Pancreat Surg"},{"issue":"6","key":"2589_CR186","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ejendo\/lvad157","volume":"189","author":"M Perrier","year":"2023","unstructured":"Perrier M, Brugel M, Gerard L, Goichot B, Lievre A, Lepage C et al (2023) Characteristics and treatment options of glucagonomas: a National study from the French group of endocrine tumors and ENDOCAN-RENATEN network. Eur J Endocrinol 189(6):575\u2013583","journal-title":"Eur J Endocrinol"},{"issue":"5904","key":"2589_CR187","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/bmj.1.5904.367","volume":"1","author":"SL Lightman","year":"1974","unstructured":"Lightman SL, Bloom SR (1974) Cure of insulin-dependent diabetes mellitus by removal of a Glucagonoma. Br Med J 1(5904):367\u2013368","journal-title":"Br Med J"},{"issue":"2","key":"2589_CR188","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000335591","volume":"95","author":"RT Jensen","year":"2012","unstructured":"Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P et al (2012) ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95(2):98\u2013119","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2589_CR189","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/gut.42.6.792","volume":"42","author":"S Angeletti","year":"1998","unstructured":"Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A et al (1998) Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42(6):792\u2013794","journal-title":"Gut"},{"key":"2589_CR190","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.diabres.2018.04.001","volume":"143","author":"L Morviducci","year":"2018","unstructured":"Morviducci L, Rota F, Rizza L, Di Giacinto P, Ramponi S, Nardone MR et al (2018) Everolimus is a new anti-cancer molecule: metabolic side effects as lipid disorders and hyperglycemia. Diabetes Res Clin Pract 143:428\u2013431","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"2589_CR191","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1507\/endocrj.EJ18-0542","volume":"66","author":"J Tanimura","year":"2019","unstructured":"Tanimura J, Nakagawa H, Tanaka T, Kikuchi A, Osada S, Tanaka Y et al (2019) The clinical course and potential underlying mechanisms of everolimus-induced hyperglycemia. Endocr J 66(7):615\u2013620","journal-title":"Endocr J"},{"issue":"1","key":"2589_CR192","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40618-023-02170-9","volume":"47","author":"A Faggiano","year":"2024","unstructured":"Faggiano A (2024) Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story. J Endocrinol Invest 47(1):35\u201346","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2589_CR193","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1634\/theoncologist.2013-0111","volume":"18","author":"M Yin","year":"2013","unstructured":"Yin M, Zhou J, Gorak EJ, Quddus F (2013) Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 18(12):1248\u20131255","journal-title":"Oncologist"},{"issue":"3","key":"2589_CR194","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s12020-016-1073-8","volume":"55","author":"X Hu","year":"2017","unstructured":"Hu X, Liu S, Liu X, Zhang J, Liang Y, Li Y (2017) DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat Insulinoma (RINm) cells via suppressing NF-kappaB activation. Endocrine 55(3):754\u2013763","journal-title":"Endocrine"},{"issue":"7","key":"2589_CR195","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.2337\/db12-1686","volume":"62","author":"AE Butler","year":"2013","unstructured":"Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62(7):2595\u20132604","journal-title":"Diabetes"},{"key":"2589_CR196","doi-asserted-by":"publisher","first-page":"1534365","DOI":"10.1155\/2019\/1534365","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang X, Chai S, Zhao X, Ji L (2019) Risk of malignant neoplasia with Glucagon-Like Peptide-1 receptor agonist treatment in patients with type 2 diabetes: A Meta-Analysis. J Diabetes Res 2019:1534365","journal-title":"J Diabetes Res"},{"issue":"4","key":"2589_CR197","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/pros.20692","volume":"68","author":"J Palmer","year":"2008","unstructured":"Palmer J, Venkateswaran V, Fleshner NE, Klotz LH, Cox ME (2008) The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine lady Transgenic prostate. Prostate 68(4):345\u2013353","journal-title":"Prostate"},{"issue":"1","key":"2589_CR198","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40618-023-02169-2","volume":"47","author":"L Barrea","year":"2024","unstructured":"Barrea L, Verde L, Annunziata G, Camajani E, Caprio M, Sojat AS et al (2024) Role of mediterranean diet in endocrine diseases: a joint overview by the endocrinologist and the nutritionist. J Endocrinol Invest 47(1):17\u201333","journal-title":"J Endocrinol Invest"},{"key":"2589_CR199","doi-asserted-by":"crossref","unstructured":"Mentella MC, Scaldaferri F, Ricci C, Gasbarrini A, Miggiano GAD (2019) Cancer Mediterranean Diet: Rev Nutrients. 11(9):2059.","DOI":"10.3390\/nu11092059"},{"issue":"8","key":"2589_CR200","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41568-022-00473-2","volume":"22","author":"CE Holbert","year":"2022","unstructured":"Holbert CE, Cullen MT, Casero RA Jr., Stewart TM (2022) Polyamines in cancer: integrating organismal metabolism and antitumour immunity. Nat Rev Cancer 22(8):467\u2013480","journal-title":"Nat Rev Cancer"},{"key":"2589_CR201","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/cancers14184402","volume":"14","author":"G Muscogiuri","year":"2022","unstructured":"Muscogiuri G, Barrea L, Cantone MC, Guarnotta V, Mazzilli R, Verde L et al (2022) Neuroendocrine tumors: A comprehensive review on nutritional approaches. Cancers (Basel) 14:18","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2589_CR202","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/10408398.2020.1832955","volume":"62","author":"G Muscogiuri","year":"2022","unstructured":"Muscogiuri G, Barrea L, Campolo F, Sbardella E, Sciammarella C, Tarsitano MG et al (2022) Ketogenic diet: a tool for the management of neuroendocrine neoplasms? Crit Rev Food Sci Nutr 62(4):1035\u20131045","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2589_CR203","doi-asserted-by":"crossref","unstructured":"Dynka D, Kowalcze K, Ambrozkiewicz F, Paziewska A (2023) Effect of the ketogenic diet on the prophylaxis and treatment of diabetes mellitus: A review of the Meta-Analyses and clinical trials. Nutrients.;15(3):500.","DOI":"10.3390\/nu15030500"},{"issue":"6","key":"2589_CR204","first-page":"527","volume":"71","author":"KK Clifton","year":"2021","unstructured":"Clifton KK, Ma CX, Fontana L, Peterson LL (2021) Intermittent fasting in the prevention and treatment of cancer. CA Cancer J Clin 71(6):527\u2013546","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2589_CR205","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000456619","volume":"105","author":"S Massironi","year":"2017","unstructured":"Massironi S, Zilli A, Bernasconi S, Fanetti I, Cavalcoli F, Ciafardini C et al (2017) Impact of vitamin D on the clinical outcome of Gastro-Entero-Pancreatic neuroendocrine neoplasms: report on a series from a single Institute. Neuroendocrinology 105(4):403\u2013411","journal-title":"Neuroendocrinology"},{"key":"2589_CR206","doi-asserted-by":"crossref","unstructured":"Albertelli M, Petolicchio C, Brasili S, Pogna A, Boschetti M, Luciano G et al (2023) Impact of vitamin D deficiency on tumor aggressiveness in neuroendocrine neoplasms. Nutrients.;15(17):3771.","DOI":"10.3390\/nu15173771"},{"issue":"2","key":"2589_CR207","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12020-021-02869-w","volume":"75","author":"B Altieri","year":"2022","unstructured":"Altieri B, Barrea L, Modica R, Bottiglieri F, de Cicco F, Muscogiuri G et al (2022) Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. Endocrine 75(2):623\u2013634","journal-title":"Endocrine"},{"issue":"1","key":"2589_CR208","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/01635581.2020.1838572","volume":"74","author":"S Artale","year":"2022","unstructured":"Artale S, Barzaghi S, Grillo N, Maggi C, Lepori S, Butti C et al (2022) Role of diet in the management of carcinoid syndrome: clinical recommendations for nutrition in patients with neuroendocrine tumors. Nutr Cancer 74(1):2\u201311","journal-title":"Nutr Cancer"},{"key":"2589_CR209","doi-asserted-by":"crossref","unstructured":"Massironi S, Panzuto F, Zilli A, Rinzivillo M, Ciliberto A, Romano E et al (2024) Nutritional aspects in neuroendocrine neoplasms. Bridging the gap between dietary interventions and cancer care strategies: a scoping review. J Endocrinol Invest. 48(2):269-281.","DOI":"10.1007\/s40618-024-02462-8"},{"key":"2589_CR210","doi-asserted-by":"crossref","unstructured":"Rondanelli M, Rigon C, Perna S, Gasparri C, Iannello G, Akber R et al (2020) Novel insights on intake of fish and prevention of sarcopenia: all reasons for an adequate consumption. Nutrients. 12(2):307.","DOI":"10.3390\/nu12020307"},{"issue":"7942","key":"2589_CR211","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/d41586-022-04430-9","volume":"613","author":"DJ Glass","year":"2023","unstructured":"Glass DJ (2023) Senescent cells damage the body throughout life. Nature 613(7942):30\u201331","journal-title":"Nature"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02589-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:33:09Z","timestamp":1757169189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02589-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":211,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02589-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Massimiliano Caprio, Sebastio Perrini and Manuela Albertelli are members of the editorial board of the Journal of Endocrinological Investigation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}